Steven R. Zeldenrust, Ph.D.
Affiliations: | 2001 | Indiana University, Bloomington, Bloomington, IN, United States |
Area:
Total Synthesis of Natural ProductsGoogle:
"Steven Zeldenrust"Mean distance: 7.74
Parents
Sign in to add mentor| David A. Williams | grad student | 2001 | Indiana University Bloomington | |
| (A transgenic mouse line expressing an amyloidogenic human transthyretin.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hwa YL, Kumar SK, Gertz MA, et al. (2016) Induction Therapy Pre-Autologous Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis: A Retrospective Evaluation. American Journal of Hematology |
| Kumar SK, Hayman SR, Buadi FK, et al. (2012) Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 119: 4860-7 |
| Dispenzieri A, Buadi F, Laumann K, et al. (2012) Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 119: 5397-404 |
| Dispenzieri A, Lacy MQ, Katzmann JA, et al. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 107: 3378-83 |
| Sharma P, Perri RE, Sirven JE, et al. (2003) Outcome of liver transplantation for familial amyloidotic polyneuropathy. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 9: 1273-80 |
| Zeldenrust SR, Skinner M, Share J, et al. (1994) A new transthyretin variant (his 69) associated with vitreous amyloid in an FAP family Amyloid. 1: 17-22 |